Considering that the existence of KRAS pathogenic variants results in activation of the intracellular RAS–RAF–MEK–ERK pathway, mitogen‐activated extracellular signal‐regulated kinase (MEK) inhibitors are expected to be key drugs for the treatment of KRAS‐mutant cancers. This evidence concerns the gene KRAS and cancer.